Vimarsana
Biggest News Aggregation in the World

Orphan Designation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Orphan Designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Orphan Designation Today - Breaking & Trending Today

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates - Vimarsana News

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

Published: May 24, 2024

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesYuxiang MaHaibo QiuMasa LasicaPrnewswire Ascentage PharmaHuafeng WangAscentage PharmaYifan ZhaiMd Anderson Cancer CenterAmerican Society Of Clinical OncologySun Yat Sen University Cancer CenterZhejiang University School Of MedicineMajor NationalDana Farber Cancer InstituteChina National Medical Products AdministrationNational Reimbursement Drug ListClinical OncologyAnnual MeetingOral ReportsChief Medical OfficerCentral TimeHematologic MalignanciesMyelodysplastic SyndromesFirst Affiliated Hospital
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress - Vimarsana News

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

Published: May 16, 2024

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Source: marketscreener.com
Related Topics:
United StatesHong KongLu YuSikander AilawadhiAscentage PharmaYifan ZhaiJunjie ChenPrnewswire Ascentage PharmaSouthern Medical UniversityEuropean Hematology AssociationChina National Medical Products AdministrationAscentage Pharma Group IncUniversity Of Texas Md Anderson Cancer CenterDana Farber Cancer InstituteMd Anderson Cancer CenterMajor NationalNational Reimbursement Drug ListEmbryonic Ectoderm DevelopmentUniversity People HospitalEuropean Hematology Association Hybrid CongressPoster PresentationsHematology Association Hybrid CongressHybrid CongressChief Medical OfficerOvercomes Ponatinib
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug ... - Vimarsana News

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug ...

Published: April 30, 2024

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug ...

Source: pr-inside.com
Related Topics:
City OfUnited KingdomPhil DaviesAnthony FarrellDavid AllmondJeremy SkillingtonHelena BatesNick BastinSam ButcherAmryt PharmaNiall GilchristGeoff NashPoolbeg PharmaNigel BirksIan OconnellCharlie BeesonInvestor Meet CompanyPoolbeg Pharma PlcTherapeutics IncOffice Of Orphan Products DevelopmentNews NetworkStrategic CommunicationsOption AgreementAcquire Orphan DrugAcquire Orphan Drug Candidate
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results - Vimarsana News

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

Published: March 26, 2024

MINNEAPOLIS, March 26, 2024 -- Panbela Therapeutics, Inc. , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today...

Source: marketscreener.com
Related Topics:
United StatesTammy GroeneJenniferk SimpsonNasdaq Stock MarketJohns Hopkins University School Of MedicinePanbela Therapeutics IncAdoption Of Commission Implementing DecisionPediatric Neuroblastoma ProgramEuropean UnionResearch AgreementAmerican Association For Cancer ResearchGlobenewswire IncSponsored Research AgreementCancer CenterEvaluate Polyamine Metabolic Inhibitor TherapyHopkins University SchoolPoster PresentationCancer ResearchClinical DataNew ApproachesNeuroblastoma TherapyTypei DiabetesCancer Risk Reduction TrialCommission Implementing DecisionOrphan Designation
Global Bispecific Antibody Market Clinical Trials Insight Report to 2029: 12 Bispecific Antibodies Generated Revenue of Over US$ 8.5 Billion in 2023 - Vimarsana News

Global Bispecific Antibody Market Clinical Trials Insight Report to 2029: 12 Bispecific Antibodies Generated Revenue of Over US$ 8.5 Billion in 2023

Published: March 13, 2024

/PRNewswire/ -- The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to...

Source: prnewswire.com
Related Topics:
Gensun BiopharmaLyvgen BiopharmaImmuneonco BiopharmaNovarock BiotherapeuticsAstellas PharmaLaura WoodEpimab BiotherapeuticsLinton PharmInnovent BiologicsAkeso BiopharmaRegeneron PharmaceuticalsJanssen Research DevelopmentOffice Hours CallBispecific Antibodies Development Proprietary Platforms InsightE St Office Hours CallLanova MedicinesBispecific Antibody MarketDrugs SalesClinical Trials InsightBispecific Antibodies Market Size YearlyQuarterly SalesBispecific Antibodies Market SizeBispecific Antibodies Market ForecastBispecific Antibodies YearlyBispecific Antibodies Regional Sales